ProcIntel Procurement Intelligence. Delivered.
DEGRADED Shows whether ProcIntel's scheduled collection system is operating normally and when the latest successful collection completed. Currently: Scheduled collection is running, but recent source failures were recorded. Last collection 4 minutes ago
Preview
Public Preview — read-only, pre-launch
← Back to Events

Private equity firm Creador in talks to buy into generic drug co Leeford Health

ProcIntel Risk Index (PRI) PRI indicates how much procurement risk attention a canonical event warrants, based on its potential impact, corroboration, linked-entity criticality, geographic or regulatory exposure, and confidence in the available evidence. — 9 · Minimal Freshness: Ageing Shows how recently the evidence supporting the event was updated. Freshness is displayed separately and does not automatically reduce PRI. Shows whether all structured inputs needed for the PRI are sufficiently assessed. Incomplete Entity Criticality data is disclosed rather than silently treated as low risk. DATA QUALITY WARNING

PRI: 9 — MINIMAL Base risk 21/100 × Low confidence multiplier (0.45). Highest contributor: Significance 40/100, normalised to this factor's 40-point cap (+16 of 40). Limiting factor: Linked-entity criticality 0/100, normalised to this factor's 30-point cap -- DATA QUALITY WARNING: no eligible entities (30 points below its maximum). DATA QUALITY WARNING: no eligible entities.

Confidence multiplier Confidence limits the final PRI when evidence is uncertain. A severe but weakly supported claim cannot reach the highest PRI bands.: 0.45 (Low) · Calculated 2026-08-03 21:13:28 (vv1).

Full contribution breakdown
  • Procurement Impact: 16 / 40 — Significance 40/100, normalised to this factor's 40-point cap
  • Corroboration: 5 / 15 — A single event -- not yet corroborated by a separate clustered event (neutral baseline, not a penalty)
  • Entity Criticality: 0 / 30 — Linked-entity criticality 0/100, normalised to this factor's 30-point cap -- DATA QUALITY WARNING: no eligible entities
  • Geographic Regulatory: 0 / 15 — 0 distinct content-linked geography/geographies
Event type
Acquisition
UUID
3a365812-e1bb-4912-9376-4bb78a7d1e76
Editorial review status
Pending (ProcIntel's own review of this record)
Event lifecycle
Breaking (the real-world state of the situation — a separate concept from review status above)
Significance
2 · Moderate
  • This type of disruption typically has a moderate procurement impact.
  • No specific geography identified yet.
  • Linked to 1 tracked entity.
  • Assessed time horizon: Short-term.
Confidence
2 · Low (distinct from each article link's own extraction confidence below)
  • Reported only by secondary sources so far — no primary/official confirmation yet.
  • Reported by a single source so far — not yet independently corroborated.
  • Some key facts (e.g. exact date) are still missing or unconfirmed.
  • Evidence was last updated within the last month.
Impact direction
Neutral or Mixed (provisional default — not yet reviewed)
Occurred at
Not yet established (no explicit date was tightly bound to the matched event text)
Record type
REAL

Source Facts

Private equity firm Creador is in advanced talks to acquire a stake. The firm expects to invest ₹800 crore in Leeford Healthcare. This acquisition would value the generic drugmaker at ₹8,000-₹8,500 crore. Leeford Healthcare is a diversified pharmaceutical and wellness company. This deal marks the company's first ownership dilution to an external investor.

Linked Signals

PublishedHeadlineSourceMatched textExtraction confidenceMethod
2026-08-03 19:34:43 Private equity firm Creador in talks to buy into generic drug co Leeford Health The Economic Times - Industry acquisition, acquire 38.5 keyword combination

Linked Entities

EntityTypeLink methodConfidenceSource article
India Country reused entity extraction 95.0 article

Spend Categories

No spend categories linked yet

Spend categories are linked by a reviewer, not assigned automatically.

Review History

DateActionPreviousNewReviewerNote
2026-08-03 21:13:28 Created — Acquisition: 'Private equity firm Creador in talks to buy into generic drug co Leeford Health' (lifecycle=Breaking) Deterministic v1 extractor —
2026-08-03 21:13:28 Pri Recalculated score=None, band=None score=1, band='Minimal' Deterministic v1 extractor PRI: 1 — MINIMAL Base risk 5/100 × Very Low confidence multiplier (0.15). Highest contributor: A single event -- not yet corroborated by a separate clustered event (neutral baseline, not a penalty) (+5 of 15). Limiting factor: No Significance score yet (event has no linked articles) (40 points below its maximum). DATA QUALITY WARNING: no eligible entities.
2026-08-03 21:13:28 Article Linked — source_item #2536 — —
2026-08-03 21:13:28 Significance Changed None 2 — —
2026-08-03 21:13:28 Confidence Changed None 2 — —
2026-08-03 21:13:28 Pri Recalculated score=1.0, band='Minimal' score=9, band='Minimal' — PRI: 9 — MINIMAL Base risk 21/100 × Low confidence multiplier (0.45). Highest contributor: Significance 40/100, normalised to this factor's 40-point cap (+16 of 40). Limiting factor: Linked-entity criticality 0/100, normalised to this factor's 30-point cap -- DATA QUALITY WARNING: no eligible entities (30 points below its maximum). DATA QUALITY WARNING: no eligible entities.